Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Journal of Clinical Medicine|March 28, 2026
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology GroupSedat Yıldız, Hacer Demir, Talha Özüdoğru, et al.Scientific Reports|April 5, 2025
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancerYasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.Anti-Cancer Drugs|June 15, 2022
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group studyÖzlem Özdemir, Baha Zengel, Yaşar Yildiz, et al.Cancer Investigation|May 20, 2021
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World ExperienceAykut Bahçeci, Semra Paydaş, Naziye Ak, et al.Journal of Chemotherapy (Florence, Italy)|March 18, 2024
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) studyHasan Cagri Yildirim, Caner Kapar, Baris Koksal, et al.Future Oncology (London, England)|October 17, 2025
Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access programDeniz Tural, Oğuzcan Özkan, Eda Eylemer Mocan, et al.Journal of Clinical Medicine|February 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective AnalysisBaris Koksal, Hasan Cagri Yildirim, Deniz Can Guven, et al.Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.Future Oncology (London, England)|May 3, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancerSeda Kahraman, Enes Erul, Mustafa Seyyar, et al.Pageof 6